Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.The company’s lead drug candidate, BPL-003, is under development for treatment-resistant depression. • ATAI stock is gaining positive traction. See what is happening here.Topline results from the eight-week core phase of the Phase 2b study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable a ...